• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Earnings Beat Altering The Investment Case For Henry Schein Stock (HSIC)?

    Simply Wall St·11/07/2026 18:23:11
    Listen to the news
    • Henry Schein reported third quarter 2026 sales of US$3,471 million and net income of US$119 million, with both basic and diluted EPS from continuing operations higher than a year earlier. The company also confirmed full year 2026 sales growth guidance of 4.5% to 5.5%.
    • The latest results show Henry Schein generating higher sales and earnings over both the third quarter and the first nine months. This provides investors with updated information on how its mix shift toward higher value products and services is translating into profitability.
    • We will now look at how Henry Schein's higher year on year earnings and confirmed sales guidance shape its investment narrative.

    Scan how Henry Schein's confirmed 2026 sales guidance compares with other healthcare players showing disciplined growth profiles using the curated 39 high quality undervalued stocks.

    Henry Schein Investment Narrative Recap

    For Henry Schein, the central belief is that shifting more activity into higher margin specialty products, technology, and own brands can steadily lift profitability while value creation targets are met. The confirmed 2026 sales outlook of 4.5% to 5.5% and year on year earnings progress keep that execution story intact rather than changing it.

    The main near term catalyst remains how effectively those mix and efficiency initiatives appear in margins through 2026. The biggest operational risk is that pricing pressure in digital equipment and any shortfall against the planned US$200 million operating income improvement dilute that margin thesis, even if sales guidance remains in place.

    The most relevant recent announcement is Henry Schein confirming 2026 total sales growth guidance at 4.5% to 5.5% while also expecting fourth quarter sales growth roughly in line with the first half of 2026. That connects the latest quarterly numbers directly to the existing multiyear efficiency and mix targets.

    For you as a shareholder, that confirmed outlook keeps attention on execution of the value creation plan, including US$200 million of operating income improvement and a US$125 million run rate by the end of 2026, alongside growth in technology and specialty segments. Progress or slippage against those markers is likely to shape how investors weigh the stock’s perceived value and risk profile.

    Henry Schein's outlook points to projected revenue of US$15.4b and earnings of US$661.2 million by 2029. This would represent 4.2% annual revenue growth and an earnings increase of about US$258 million from US$403.0 million today.

    Uncover how Henry Schein's fair value indicates a 14% potential upside to its current price, which could narrow quickly as expectations reset.

    NasdaqGS:HSIC 1-Year Stock Price Chart
    NasdaqGS:HSIC 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame Henry Schein around recurring software and at home care as the real catalyst. Before this guidance, the bullish cohort was pencilling in revenue of about US$15.9b and earnings of roughly US$847.8 million by 2029. You can use those richer assumptions as a contrast and explore how views might shift after this latest update.

    Explore another Henry Schein fair value estimate, including one that suggests as much as 157% upside from the current price.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Henry Schein?

    Once you have a view on Henry Schein, it often helps to compare it with other businesses that fit different risk and quality profiles using the Simply Wall St Screener.